Yovanni Casablanca
Atrium Levine Cancer - Carolinas Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yovanni Casablanca as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:19 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07672782 · Tisotumab Vedotin in Squamous Cell Carcinoma of the VulvaGOG Foundation · not yet recruiting · Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:19 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.Gynecol Oncol · 201837 citationsRCR 1.3
- Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.Obstet Gynecol · 202225 citationsRCR 2.0
- Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.Clin Cancer Res · 202322 citationsRCR 1.9
- Intracervical block and pain perception during the performance of a hysterosalpingogram: a randomized controlled trial.Obstet Gynecol · 200720 citationsRCR 0.9
- The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.Gynecol Oncol · 20228 citationsRCR 0.6